
JTE-013
CAS No. 383150-41-2
JTE-013( —— )
Catalog No. M22938 CAS No. 383150-41-2
JTE-013 is an effective and specific antagonist of S1P2. JTE-013 suppresses the specific binding of radiolabeled S1P to human and rat S1P2 (IC50s: 17 nM and 22 nM, respectively).JTE-013 is a S1P2 antagonist. JTE-013 (50-200 μM;?1-3 days) decreased cell viability.
Purity : >98% (HPLC)






Size | Price / USD | Stock | Quantity |
5MG | 63 | In Stock |
![]() ![]() |
10MG | 91 | In Stock |
![]() ![]() |
25MG | 202 | In Stock |
![]() ![]() |
50MG | 302 | In Stock |
![]() ![]() |
100MG | Get Quote | In Stock |
![]() ![]() |
200MG | Get Quote | In Stock |
![]() ![]() |
500MG | Get Quote | In Stock |
![]() ![]() |
1G | Get Quote | In Stock |
![]() ![]() |
Biological Information
-
Product NameJTE-013
-
NoteResearch use only, not for human use.
-
Brief DescriptionJTE-013 is an effective and specific antagonist of S1P2. JTE-013 suppresses the specific binding of radiolabeled S1P to human and rat S1P2 (IC50s: 17 nM and 22 nM, respectively).JTE-013 is a S1P2 antagonist. JTE-013 (50-200 μM;?1-3 days) decreased cell viability.
-
DescriptionJTE-013 is an effective and specific antagonist of S1P2. JTE-013 suppresses the specific binding of radiolabeled S1P to human and rat S1P2 (IC50s: 17 nM and 22 nM, respectively).JTE-013 is a S1P2 antagonist. JTE-013 (50-200 μM;?1-3 days) decreased cell viability.?JTE-013 shows 4.2% inhibition of S1P3 and does not antagonize S1P1 at concentrations up to 10 μM.?JTE-013 (10-1000 nM;?30 mins) reverses S1P-induced Akt inhibition and inhibits S1P-induced ERK activation.JTE-013 (gavage;?30 mg/kg daily for 14 consecutive days) decreases tumor size and tumor weight.?the modification of JTE-013 to produce the AB1 compound improved potency, intravenous pharmacokinetics, cellular activity, and antitumor activity in NB and may have enhanced clinical and experimental applicability.
-
In VitroJTE-013 (50-200 μM; 1-3 days) reduces cell viability. JTE-013 (10-1000 nM; 30 mins) reverses S1P-induced Akt inhibition and inhibits S1P-induced ERK activation.JTE-013 displays 4.2% inhibition of S1P3 and does not antagonize S1P1 at concentrations up to 10 μM. Cell Viability AssayCell Line:SK-N-AS cells Concentration:50, 100, 150, 200 μ Incubation Time:1-3 days Result:Reduced cell viability.Western Blot Analysis Cell Line:SK-N-AS cells Concentration:10, 100, 1000 nM Incubation Time:30 mins Result:Reversed S1P-induced Akt inhibition and inhibited S1P-induced ERK activation.
-
In VivoJTE-013 (gavage; 30 mg/kg daily for 14 consecutive days) reduces tumor size and tumor weight. Animal Model:Six-week-old female athymic NCr-nu/nu nude mice Dosage:30 mg/kg Administration:Gavage; daily for 14 consecutive days Result:Reduced tumor size and tumor weight.
-
Synonyms——
-
PathwayGPCR/G Protein
-
TargetS1P Receptor
-
RecptorS1P2
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number383150-41-2
-
Formula Weight408.29
-
Molecular FormulaC17H19Cl2N7O
-
Purity>98% (HPLC)
-
SolubilityDMSO:100 mg/mL (244.92 mM; Need ultrasonic)
-
SMILESCC(C1=C2C(N(C)N=C2C)=NC(NNC(NC3=CC(Cl)=NC(Cl)=C3)=O)=C1)C
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. Li MH, et al. Antitumor Activity of a Novel Sphingosine-1-Phosphate 2 Antagonist, AB1, in Neuroblastoma. J Pharmacol Exp Ther. 2015 Sep;354(3):261-8.
molnova catalog



related products
-
GSK2018682
GSK2018682 is an agonist of sphingosine-1-phosphate receptor ?(s1p1) and (s1p5) agonist(pEC50s of 7.7 and 7.2respectively).
-
W140 HBr
[(3S)-3-amino-4-(3-hexylanilino)-4-oxobutyl]phosphonic acid;hydrobromide is a S1P1 antagonist with Ki of 2.84 μM.
-
4-Deoxypyridoxine hy...
4-Deoxypyridoxine (hydrochloride) inhibits the degradation of intracellular S1P by inhibiting S1P lyase (SPL) activity, minimized the chemically induced apoptosis of insulinoma cell lines as S1P did.